NEWS

AskBio Publishes 12-Month Phase 1 AB-1002 Gene Therapy Data for Congestive Heart Failure in Nature Medicine

Long-Term Data Demonstrate Safety and Preliminary Efficacy of Investigational One-Time Gene Therapy in Patients with Non-Ischemic Heart Failure  AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced the publication…

Read MoreAskBio Publishes 12-Month Phase 1 AB-1002 Gene Therapy Data for Congestive Heart Failure in Nature Medicine

Pimicotinib Treatment Shows Lasting Tumor Response and Improved Pain and Function in TGCT Patients

Merck Announces Promising Long-Term Results of Pimicotinib in Phase 3 MANEUVER Trial for TGCT Treatment Merck, a leading global science and technology company, has today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial. This pivotal…

Read MorePimicotinib Treatment Shows Lasting Tumor Response and Improved Pain and Function in TGCT Patients
Drug Farm, Cincinnati Children’s Partner on ALPK1

Drug Farm, Cincinnati Children’s Partner on ALPK1 Inhibitor for Heart Disease and Blood Cancers

Drug Farm, a private biotechnology company pioneering the use of genetics and artificial intelligence to discover and develop innovative immune-modulating therapies, announced today that it has entered into a Material Transfer Agreement (MTA) with Cincinnati Children’s Hospital Medical Center (CCHMC).…

Read MoreDrug Farm, Cincinnati Children’s Partner on ALPK1 Inhibitor for Heart Disease and Blood Cancers
NucleoBio and PreCheck Health Partner

NucleoBio and PreCheck Health Partner on Non-Invasive Prostate Cancer Test

NucleoBio, Corp., a biotechnology innovator in precision oncology diagnostics, has announced a new strategic collaboration with PreCheck Health Services, a high-complexity CLIA-certified and CAP-accredited clinical laboratory. The partnership will support the clinical development and processing of Prostac™, NucleoBio’s proprietary diagnostic…

Read MoreNucleoBio and PreCheck Health Partner on Non-Invasive Prostate Cancer Test
Apollo’s Camoteskimab Meets Phase 2a Endpoint in Atopic Dermatitis

Apollo’s Camoteskimab Meets Phase 2a Endpoint in Atopic Dermatitis

Apollo Therapeutics Reports Positive Phase 2a Results for Camoteskimab in Atopic Dermatitis Apollo Therapeutics, a leading portfolio biopharmaceutical company, announced today positive topline results from its Phase 2a CHAMELEON trial evaluating camoteskimab, an investigational anti-IL-18 monoclonal antibody, in patients with…

Read MoreApollo’s Camoteskimab Meets Phase 2a Endpoint in Atopic Dermatitis
Areteia Reports Positive Phase III Results

Areteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma

Areteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma Areteia Therapeutics, Inc. announced today that its Phase III EXHALE-4 clinical trial has met key efficacy and safety endpoints for dexpramipexole, an investigational oral therapy being developed as…

Read MoreAreteia Reports Positive Phase III Results for Oral Dexpramipexole in Eosinophilic Asthma